Purpose of review The relationship between pancreatic ductal adenocarcinoma (PDAC) and diabetes mellitus (DM) is complex. We reviewed the recent medical literature regarding the effect of anti-diabetic medication on PDAC risk and survival, risk of PDAC in DM, and role of DM in early detection of PDAC. Recent findings Studies report that while some anti-diabetic medications (e.g., metformin) may decrease the risk of PDAC, others (insulin, sulfonylureas and incretin-based therapies) may increase the risk. However, these observations may be subject to protopathic biases. Metformin's anti-tumor activity may have influence overall survival of PDAC, but epidemiological reports have largely been inconsistent to defend these findings due to heterogeneous methodologies. There is congruent data to support the association between DM and PDAC, with an inverse relationship to DM duration. Older subjects with new-onset DM are the only known high-risk group for PDAC, and strategy using this group for early detection has led to development of clinical risk prediction models that define a very high-risk PDAC group. Summary Role of anti-diabetic medication in PDAC risk modification or survival is controversial. With successful efforts to distinguish type 2-DM from PDAC-DM using riskstratifying models, there is an opportunity to initiate screening protocols for early detection of PDAC in a sub-set of DM subjects.
Introduction
The relationship between diabetes mellitus (DM) and pancreatic ductal adenocarcinoma (PDAC) has been known for more than a century. However, understanding of this relationship is complicated with existence of bidirectional link between the two conditions. Longstanding DM (LSDM) has been well established as a risk factor for development of PDAC, but growing epidemiologic, clinical, and experimental evidence suggest that new-onset DM (NOD) is a paraneoplastic phenomenon in a subset of patients that precedes PDAC diagnosis [1] . Recognizing NOD as a clinical manifestation of occult PDAC has important implication in the field of early detection of PDAC. Ability to distinguishing NOD caused by PDAC, which is distinct from NOD of type 2, provides an opportunity to identify and diagnose PDAC at a stage at which curative therapy is possible. More recent, studies also suggest anti-diabetic medications (ADMs) directly affect the key factors mediating the association between type 2-DM and PDAC, with an influence on cancer development, progression, and outcome [2•] . This has led to increasing interest in understanding the causal relationship between ADM use and the risk of PDAC and whether it has a role in PDAC prevention and treatment. Here, we discuss the role of ADMs in the risk modification of PDAC and its influence on overall survival of PDAC along with a current opinion in the field of DM and PDAC. We also summarize the advances made in the field of early detection of PDAC in the past year and selected the best publications, which merited attention, for this review.
PDAC risk and anti-diabetic medications
Epidemiological studies have found that ADM agents reducing insulin resistance (such as metformin and thiazolidinedione) reduce risk of PDAC, whereas ADM agents increasing levels of circulating insulin (such as sulfonylureas [insulin secretagogues] and insulin analogs) are associated with an increased risk for PDAC [3] [4] [5] [6] . Data on relatively new ADMs, incretin-based analogues, is sparse, with conflicting findings and no clear association [7•, 8, 9] . Although, results of current epidemiological studies suggest a relationship between ADM use and PDAC risk, these data should be inferred with caution.
Metformin use and risk of PDAC
Metformin is the most widely used ADM for type 2 DM. Metformin acts by decreasing circulating insulin and insulin-like growth factor (IGF) levels and causes inhibition of mitochondrial glycerophosphate dehydrogenase and increases AMP-activated protein kinase (AMPK), consequently leading to an altered hepatocellular redox state, reduced conversion of lactate and glycerol to glucose, and decreased hepatic gluconeogenesis [2•, 10] . Chen et al. showed that metformin suppressed cancer initiation and progression in genetic mouse model of PDAC [11] . Considering this, there is growing interest to investigate the role of metformin as a promising preventive agent for PDAC. Consistent with reports by Wang et al., the most recent meta-analysis reported on pooled data from published studies also found that risk of PDAC was lower in metformin users (relative risk [RR] = 0.61) [12, 13] . However, the studies included in meta-analyses vary considerably in their methodology and do not account for the fact that PDAC can cause and/or worsen DM. Olson et al. showed that there is worsening of DM months prior to PDAC diagnosis leading to initiation of insulin and therefore altering the natural course of DM treatment in PDAC subjects [14] . In a large case-control observational study, Bodmer et al. addressed this limitation by adjusting for 2-year cancer latency period and found no association between metformin use and future PDAC risk [5] . Similar observations were also noted in the two randomized clinical trials comparing metformin use with other ADMs or placebo for type 2 DM subjects [13] . Due to escalation of ADM therapy from metformin to more potent anti-glycemic agents in DM subjects with undiagnosed PDAC introduces unintended biases and leads to overestimation of metformin's protective effect. So far, current epidemiological studies have been inconsistent in firmly establishing a protective effect of metformin therapy in PDAC.
Insulin use and risk of PDAC
Insulin therapy is often required with natural progression of type 2 DM. Insulinglargine, the long-acting insulin analog, is the most widely used long-acting insulin. Experimental data suggests insulin has potential mitogenic and antiapoptotic effects in cultured cancer cells through activation of the IGF-1 pathway [15, 16] . A systematic review by Colmers et al., found that new use of insulin was associated with an increased risk of PDAC (RR, 3.18) [4] . A similar risk of PDAC is also reported with use of sulfonylureas (insulin secretagogues) routinely used in DM treatment [5, 6, 13] . Recently, these observations seem to be confirmed by Lee et al., who analyzed a Korean population-based cohort of subjects with and without DM and reported that risk of PDAC increases in patients after initiating therapy with sulfonylureas (HR, 1.73) and insulin (HR, 2.86) compared to no drug exposure group [17] . Some have speculated a direct causal relationship between insulin and PDAC occurrence secondary to anabolic effect of insulin on tumor cells [18] . However, if this were to be true, then a steadily increasing risk of PDAC should be noted with an increasingly longer exposure to these therapies. In contrast, all these studies show that increased risk is observed primarily in the months immediately after initiating therapy, suggesting an underlying undiagnosed PDAC causing uncontrolled DM. This is referred as protopathic bias, which arises when the initiation of a drug (exposure) occurs in response to a clinical manifestation of the disease (at this point undiagnosed) under study outcome [19] . Therefore, we believe, escalation of therapy to insulin for uncontrolled DM may be a sign of undiagnosed PDAC, especially when occurring in face of unintentional weight loss and worsening hyperglycemia [1] .
Incretin-based therapy and risk of PDAC
Over the last decade, the worldwide prevalence of type 2 DM has increased the use of incretin-based drugs. There are two types of incretin-based drugs, glucagon-like peptide-1 receptor agonist (GLP-1) and dipeptidyl peptidase-IV (DPP-IV) inhibitors, both with pharmacological effects on the interaction between the gut and endocrine system [20] . While incretin-based therapy has a superior efficacy in controlling blood glucose compared to other ADMs in type 2 DM, studies suggest that these incretin mimetics may increase the risk of PDAC development [21] [22] [23] . There are various observational and randomized controlled clinical trials conducted to establish this association [22] [23] [24] [25] [26] . A meta-analysis by Chen et al. reported from pooled data of randomized controlled trials showed incretin-based therapies is not associated with increased risk of PDAC (RR, 0.70) [7] . Interestingly, they report a lower incidence of pancreatic neoplasms in incretin-based groups than those in placebo or nonincretin-based ADMs in studies with longer follow-up period. In contrast, Boniol et al. analyzed results from two large retrospective cohorts and observed that recent prescription of incretin therapy is associated with an increased risk of PDAC compared to other ADMs [8] . We believe the reason for an increase risk after incretin-based therapy is likely consequence of an occult PDAC that provokes or aggravates DM and therefore confounds the risk association.
PDAC survival and anti-DM medication
There are numerous studies showing influence on survival with ADM use, but till date, effect of metformin or other ADMs on clinical outcomes in PDAC-DM patients remain controversial. Overall, the influence of ADM on PDAC survival is confounded by observation that DM itself is associated with poor outcomes in PDAC. Hart et al. compared PDAC subjects with and without DM and reported that PDAC tumors with DM have a larger tumor size and higher CA19-9 levels, factors inversely related to PDAC prognosis [27] . In addition, Sharma et al. showed that poorly differentiated PDAC tumors are more likely to be associated with worsening hyperglycemia and DM, which is well known to be associated with poorer outcomes [28•] .
Effect of metformin on PDAC survival
There are growing numbers of articles focusing on the effectiveness of metformin on survival of PDAC patients with DM. In the last year, there are four meta-analyses and two observational studies addressing this relationship [29] [30] [31] [32] [33] [34] . The four metaanalyses include a total of 15 unique studies (13 observational and 2 RCTs) and conclude that metformin in comparison to non-metformin users in PDAC is associated with relative benefit in overall survival in observational studies, but not in randomized controlled studies [29] [30] [31] [32] . In contrast, Frouws et al., who analyzed 907 patients with PDAC-DM, including 77 patients treated with metformin, reported no survival benefit in patients with metformin use compared to non-users [33] . However, this study was limited by small proportion of patients with treatment on ADMs.
It is important to note that even though the results from meta-analyses support the notion that metformin use may improve the overall survival of PDAC-DM patients, most studies included are subject to immortal time bias. Immortal time is a span of cohort follow-up during which, because of exposure definition, the outcome under study could not occur. To control for this bias, Chaiteerakij et al. used time-varying covariate analysis methods and showed no benefit of metformin therapy on PDAC overall survival [35••] . When the analysis was performed by using the conventional Cox model, an artificial survival benefit of metformin was detected [35••] . This highlights the importance of patient selection and appropriate statistical analysis methods when studying medication exposure and cancer survival.
Effect of other ADMs on PDAC survival
While there are several studies looking at survival benefit with metformin in PDAC subjects, there are few reports related to other oral hypoglycemic agents and insulin use. Zhou et al. investigated the association between ADM (insulin, sulfonylurea, and thiazolidinedione) treatment and survival of PDAC and found no benefit of insulin, sulfonylureas, or thiazolidinedione [30] . So far, there is no data supporting any survival benefit with incretin-based therapy.
PDAC risk and diabetes
About 45 to 65% of patients with PDAC have DM at diagnosis, and the proportion of patients presenting with new-onset DM is nearly 25%. Conversely, there is consistent data to support that DM imparts a 2-fold increased risk for PDAC. However, this risk is influenced by DM duration and method of ascertainment of DM used to estimate PDAC risk.
Risk of PDAC changes with duration of DM
It is now well established, based on several observational studies and metaanalyses, that individuals with DM have an increased risk for PDAC compared to non-DM subjects, with risk being inversely associated with DM duration. The latest meta-analysis by Tan et al. systematically reviewed and included all studies in the last 10 years (n = 11; n = 14,399) and concluded that DM was associated with a 2-fold increased risk for PDAC (RR, 1.63) [36] . When stratified based on DM duration, they showed that patients with recent-onset DM (G 2 years) had higher incidence of PDAC compared to patients with 2-5 years of DM. These findings were confirmed by Makhoul et al. who reported similar risk association in the Veterans Administrative (VA) database after controlling for matching factors (age, gender, body mass index etc.) between DM and no DM subjects (HR, 2.17) [37] . As expected, they also noted the inverse relationship of PDAC risk with DM duration, with increased incidence of PDAC persisting only in the first 5 years after DM diagnosis. This highlights the importance of distinguishing new-onset DM (NOD, defined as DM of G 3 years duration)
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Clinical and experimental data suggest that NOD is a cancer effect (paraneoplastic clinical manifestation), whereas LSDM is modest pathogenic risk factor [1] . Pannala et al. showed amelioration of NOD, but not LSDM, following resection of PDAC, which further supports this observation [38] . Therefore, it is not surprising that compared to general population, the NOD population has a 6-8-fold higher 3-year risk (high-risk group), whereas LSDM has 1.5-2.0-fold lifetime risk (low risk group) (Fig. 1) [1, 39, 40] . Even though all these observational cohort studies and meta-analyses clearly establish the risk association between DM and PDAC, by contaminating LSDM with NOD, they seriously underestimate the overall PDAC risk.
Degree of risk of PDAC is dependent on method of ascertainment of DM
A proportion of patients with pre-DM progresses to DM over time. Physicians, knowing that pre-DM and DM may be reversible or delayed by weight loss and exercise, tend not to label patients as having DM until lifestyle changes fail to work. Thus, physician diagnosis of NOD may be delayed by months to years after patients meet glycemic criteria for new-onset DM, which is often euphemistically coded as "hyperglycemia," "pre-diabetes," or "glucose intolerance." This has significant implications for its utility for prediction of early PDAC.
Aggarwal et al. showed that in a primary care setting, in comparison to type 2 NOD, a disproportionately higher proportion of PDAC subjects with NOD fail to receive a DM diagnosis, due to the relatively short duration of DM before PDAC [ . This highlights that using physician diagnosis-NOD underestimates the incidence of PDAC in DM. Aggarwal et al. also reported that physician diagnosis-NOD is closer to PDAC diagnosis than the glycemic onset of NOD with median onset from onset to diagnoses being 3 months (range, 1 to 14 months), thus shortening the already narrow "window of opportunity" to intercept PC early [41••] .
Onset of DM may occur 4 to 7 years before its clinical diagnosis [46] . Fraser et al. reported a delay of 3.7 years between initial hyperglycemia and clinician's diagnosis date of DM, and delay in diagnosis was attributed to clinician inertia (provider factors) rather than patient factors [47] . Thus, new physician diagnosis of DM should not be confused with new-onset DM. As alluded earlier, there is a 1.5-fold increased risk of PDAC in LSDM patients compared to 6-to 8-fold risk in NOD patients, and a delay in physician diagnosis of DM by~3 years likely reflects a PDAC risk in LSDM than true NOD. This would again lead to falsely low estimation of PDAC risk in NOD. For a successful early detection strategy using NOD as the trigger, it is important to use glycemic-defined rather than physician-diagnosed NOD and we advocate the use of definition of the American Diabetes Association for DM.
Risk of PDAC in pre-DM
Pre-DM is defined by fasting plasma glucose levels of 100-125 mg/dL, a 2-h plasma glucose level of 140-100 mg/dL, or a glycosylated Hb of 5.7-6.4% [48] . Recently Sharma et al. investigated the pre-clinical progression of invasive PDAC in a case-control design using blood glucose levels as a biomarker for PDAC [28•] . With 6-monthly fasting blood glucose level data up to 60 months prior to PDAC diagnosis in cases and age-and gender-matched controls, they showed that PDAC-induced hyperglycemia develops~36 months prior to cancer diagnosis. From an early detection standpoint, these observations suggest that distinguishing PDAC-induced hyperglycemia from pre-DM of type 2 could lead to earlier detection of PDAC. However, this will require a highly specific biomarker/clinical model to enrich the pre-DM cohort for PDAC, as nearly 86 million adults in the USA are believed to have pre-DM [48] . Optimistically, with recent developments in identifying very-high-risk groups for PDAC within NOD, similar strategies may be applied to subjects with pre-DM to help detect early PDAC.
Role of DM in early detection of PDAC
PDAC has a dismal (9%) 5-year survival, largely because the majority (85%) of PDAC is diagnosed at an advanced stage. Developing strategies for early detection of resectable sporadic PDAC are critical for improving survival. Since PDAC is uncommon, a 3-step sieve approach (DEF) to its early detection has been suggested: (1) define a high-risk group for PDAC, (2) enrich the high-risk group further for PDAC, and (3) find the lesion in the highly enriched cohort [49] .
Define: new-onset diabetes as the first sieve
Screening for sporadic PDAC has so far been considered unrealistic because of its low incidence in the general population and lack of well-defined high-risk groups to screen for sporadic PDAC. The only known high-risk group for sporadic PDAC is that of subjects 9 50 years of age with NOD [39] . Chari et al. first reported in a population-based study that approximately 1% of NOD (defined by glycemic criteria) will be diagnosed with PDAC in 3-year period [39] . Sharma et al. recently validated these findings in another populationbased study using similar glycemic criteria for NOD [45••] . These observations suggest that DM is a biomarker of early-stage PDAC and identifying patients with NOD at their onset would offer the opportunity of early detection. However, NOD is relatively common with an expected annual incidence in USA being 1% [50] . The population of USA over the age of 50 years is 108 million, of which 1% will have incident NOD (i.e.,~1.1 million) [51] . Based on estimates by Chari et al. and Sharma et al., 1% of this NOD population will be diagnosed with PDAC, i.e., approximately 11,000 subjects. Conversely, expected rate of sporadic PDAC in USA is 55,400 and NOD forms~20% of all PDAC, which comprises of 11,100 subjects. This puts into perspective that screening in NOD subjects for PDAC would potentially capture one fourth of sporadic PDAC.
Enrich: clinical models and biomarkers
Since type 2 DM is a very prevalent disease, screening for PDAC in this population may not be feasible. Therefore, it is important to enrich the NOD population further to identify individuals who would benefit most from screening. Boursi et al. developed a risk prediction model for PDAC in NOD population using The Health Improvement Network (THIN) database UK [43••] . In their cohort of 109,385 NOD subjects, 0.4% was diagnosed with PDAC within 3 years of NOD diagnosis. Their final prediction model was based on demographic, behavioral, and clinical variables with predicted risk threshold of 44.7% sensitivity, 94% specificity, and a positive predictive value of 2.6% (at 1% over 3 years). However, the model used one physician diagnosis of NOD, which may have underestimated their baseline disease prevalence to~0.4% as explained earlier. Sharma et al., developed a clinical model called Enriching New-onset Diabetes for Pancreatic Cancer (ENDPAC) score using glycemic definition of NOD [45••] . The model used three parameters: age, change in blood glucose, and delta weight loss and risk stratified the NOD subjects into three groups based on 3-year PDAC risk: low (G 0.1%), intermediate (~0.5%), and very high (~4%). The score of 9 3 had a sensitivity and specificity of 80%. However, the study was limited by small numbers of PDAC events in the validation cohort and needs confirmation in other large cohorts before being implied in clinical practice. The development of these clinical models shows encouraging preliminary results in differentiating T2-NOD from PDAC-NOD.
The only available biomarker that is currently used clinically in PDAC is CA19-9. Choe et al. evaluated the utility of CA19-9 levels as a screening indicator of PDAC in asymptomatic NOD subjects (n = 5111 asymptomatic NOD of which 87 [1.7%] developed PDAC) and reported in patients, especially with high serum bilirubin, CA19-9 was a useful marker for predicting cancer [52] . Study by Murakami et al. proposed a cut-off value for CA19-9 for PDAC screening in DM subjects using a matched case-control design and showed serum CA19-9 levels of 9 75 U/mL had a sensitivity and specificity of 69.5 and 98.2%, respectively, to classify DM patients with or without PDAC [53] . However, it is well known that the usefulness of CA19-9 fades with increasing lead time and its power to discriminate between two types of DM will likely be low during the pre-diagnostic phase of PDAC [54] . Balasenthil et al., investigated genomic-based plasma TFP1/TNC-FN III-C/CA19-9 panel and noted it improved CA19-9 performance in all early-stage cohorts, including discriminating stage IA/IB/IIA, stage IIB, and all early-stage cancers from healthy controls [55] . They concluded TFP1/TNC-FN III-C migration signature adds statistical significance to CA19-9's predictive power to detect early-stage PDAC. But, it is important to note that these biomarkers are tested in samples collected at PDAC diagnosis which may not reflect metabolic abnormalities occurring during the pre-diagnostic phase. Therefore, whether these biomarkers maintain their predictiveness with increasing lead time needs to be validated in prediagnostic samples. The volume of smallest tumor associated with hyperglycemia was estimated to be 1.1 to 2.0 mL, and this volume doubles 4 to 5 times in size by the point of cancer at diagnosis (average size: 8.0-12.0 mL), providing ample of window of opportunity to find the lesion on imaging. Whether current imaging modalities (computerized tomography [CT] , magnetic resonance imaging [MRI], or endoscopic ultrasound [EUS]) will be able to detect such tumors is yet unanswered. An important finding of that study was the largest diameter of PDAC tumors at the DM diagnosis was estimated to be 2-4 cm, which provides hope that tumors at DM onset may be detected using CT or EUS. Results from prior studies by Pelaez-Luna et al. and Gangi et al. investigating the pre-diagnostic imaging scans suggest that nearly half of the PDAC subjects with CT scans obtained between 2 and 18 months prior to cancer diagnosis were identified as being diagnostic or suspicious for PDAC [56, 57] . These studies included scans done using low-quality CT techniques and therefore may underestimate the actual findings. In addition, Pelaez-Luna et al.'s results suggest that resectability of PDAC can be significantly improved if it is detected at least 6 months prior to its clinical diagnosis and that DM occurred at a resectable stage of disease [56] . This implies finding PDAC early in the NOD subjects should lead to a stage shift. As currently, 80% of PDAC at diagnosis have metastatic disease and are unresectable, finding PDAC even 3 months before its diagnosis should lead to survival benefit beyond lead time.
Feasibility of screening in NOD for PDAC
Some may debate screening for PDAC in patients with NOD may not be feasible with risk being only 1%, and imaging scanning of the pancreas as screening procedures would be neither cost-effective nor sensitive or specific [42] . To this end, Bruenderman et al. estimated the screening cost for PDAC using MRI or magnetic resonance cholangiopancreatography for 3 years among individuals with NOD older than 50 years with weight loss and reported cost per added year ranges from $356.42 based on Medicare costs to $1418.92 based on national average [58•] . In comparison to other solid organs (lung, breast, colon), screening for PDAC in this subset of NOD was reported to be affordable and cost-effective [59] [60] [61] . Moreover, with new developments in risk prediction models such as ENDPAC or UK THIN database, the targeted NOD population needing imaging significantly decreases the burden of screening.
Conclusions
Despite several reports, the role of ADM in risk association and influence on survival of PDAC remains controversial. The relationship of DM with PDAC is bidirectional with long-standing DM being a modest risk factor for development of PDAC whereas new-onset DM being an effect. Following principles of define, enrich, and find strategy for early detection of PDAC, there has been significant progress in the field, with identification of NOD as a high-risk population (define), clinical risk prediction models distinguishing type 2-NOD from PDAC-NOD (enrich), and opportunities to design future prospective protocols for interventional imaging studies in this enriched NOD cohort (find). The hope is to capture a large percentage of those with resectable, early-stage PDAC that are currently being diagnosed late.
